Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith CA, D'Alessandro A, Jordan CT. Jones CL, et al. Among authors: amaya m. Cell Stem Cell. 2020 Nov 5;27(5):748-764.e4. doi: 10.1016/j.stem.2020.07.021. Epub 2020 Aug 20. Cell Stem Cell. 2020. PMID: 32822582 Free PMC article.
Targeting the IDH2 Pathway in Acute Myeloid Leukemia.
Amaya ML, Pollyea DA. Amaya ML, et al. Clin Cancer Res. 2018 Oct 15;24(20):4931-4936. doi: 10.1158/1078-0432.CCR-18-0536. Epub 2018 May 16. Clin Cancer Res. 2018. PMID: 29769206 Review.
Venetoclax for AML: changing the treatment paradigm.
Pollyea DA, Amaya M, Strati P, Konopleva MY. Pollyea DA, et al. Among authors: amaya m. Blood Adv. 2019 Dec 23;3(24):4326-4335. doi: 10.1182/bloodadvances.2019000937. Blood Adv. 2019. PMID: 31869416 Free PMC article.
Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia.
Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Ramsey HE, Savona MR, Smith CA, Jordan CT. Pei S, et al. Among authors: amaya ml. Cancer Discov. 2020 Apr;10(4):536-551. doi: 10.1158/2159-8290.CD-19-0710. Epub 2020 Jan 23. Cancer Discov. 2020. PMID: 31974170 Free PMC article.
The Hepatic Microenvironment Uniquely Protects Leukemia Cells through Induction of Growth and Survival Pathways Mediated by LIPG.
Ye H, Minhajuddin M, Krug A, Pei S, Chou CH, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, D'Alessandro A, Jordan CT. Ye H, et al. Among authors: amaya ml. Cancer Discov. 2021 Feb;11(2):500-519. doi: 10.1158/2159-8290.CD-20-0318. Epub 2020 Oct 7. Cancer Discov. 2021. PMID: 33028621 Free PMC article.
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia.
Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, Jordan CT, Smith C, Gutman JA, Pollyea DA. Cherry EM, et al. Among authors: amaya m. Blood Adv. 2021 Dec 28;5(24):5565-5573. doi: 10.1182/bloodadvances.2021005538. Blood Adv. 2021. PMID: 34610123 Free PMC article.
Machine Learning-Based Exploratory Clinical Decision Support for Newly Diagnosed Patients With Acute Myeloid Leukemia Treated With 7 + 3 Type Chemotherapy or Venetoclax/Azacitidine.
Islam N, Reuben JS, Dale J, Gutman J, McMahon CM, Amaya M, Goodman B, Toninato J, Gasparetto M, Stevens B, Pei S, Gillen A, Staggs S, Engel K, Davis S, Hull M, Burke E, Larchick L, Zane R, Weller G, Jordan C, Smith C. Islam N, et al. Among authors: amaya m. JCO Clin Cancer Inform. 2022 Sep;6:e2200030. doi: 10.1200/CCI.22.00030. JCO Clin Cancer Inform. 2022. PMID: 36194842
Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
Gutman JA, Winters A, Kent A, Amaya M, McMahon C, Smith C, Jordan CT, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Gutman JA, et al. Among authors: amaya m. Haematologica. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681. Haematologica. 2023. PMID: 37051756 Free PMC article. Clinical Trial.
224 results